Suppr超能文献

实施成本效益分析:需要具备哪些条件?

Implementing CER: what will it take?

作者信息

Biskupiak Joseph E, Dunn Jeffrey D, Holtorf Anke-Peggy

机构信息

University of Utah, College of Pharmacy, Dept. of Pharmacotherapy, 421 Wakara Way, Salt Lake City, UT 84108, USA.

出版信息

J Manag Care Pharm. 2012 Jun;18(5 Supp A):S19-29. doi: 10.18553/jmcp.2012.18.s5-a.S19.

Abstract

BACKGROUND

Comparative effectiveness research (CER) is undeniably changing how drugs are developed, launched, priced, and reimbursed in the United States. But most organizations are still evaluating what CER can do for them and how and when they can utilize the data. A roundtable of stakeholders, including formulary decision makers, evaluated CER's possible effects on managed care organizations (MCOs) and what it may take to fully integrate CER into decision making.

OBJECTIVES

To examine the role of CER in current formulary decision making, compare CER to modeling, discuss ways CER may be used in the future, and describe CER funding sources.

SUMMARY

While decision makers from different types of organizations, such as pharmacy benefit management (PBM) companies and MCOs, may have varying definitions and expectations of CER, most thought leaders from a roundtable of stakeholders, including formulary decision makers, see value in CER's ability to enhance their formulary decision making. Formulary decision makers may be able to use CER to better inform their coverage decisions in areas such as benefit design, contracting, conditional reimbursement, pay for performance, and other alternative pricing arrangements. Real-world CER will require improvement in the health information technology infrastructure to better capture value-related information. The federal government is viewed as a key driver and funding source behind CER, especially for infrastructure and methods development, while industry will adapt the clinical development and create increasing CER evidence. CER then needs to be applied to determining value (or cost efficacy).

CONCLUSIONS

It is expected that CER will continue to grow as a valuable component of formulary decision making. Future integration of CER into formulary decision making will require federal government and academic leadership, improvements in the health information technology infrastructure, ongoing funding, and improved and more consistent methodologies.

摘要

背景

无可否认,比较效果研究(CER)正在改变美国药物的研发、上市、定价和报销方式。但大多数机构仍在评估CER能为它们做什么,以及如何、何时利用这些数据。一个由包括处方集决策者在内的利益相关者组成的圆桌会议,评估了CER对管理式医疗组织(MCO)可能产生的影响,以及将CER全面纳入决策过程所需的条件。

目标

研究CER在当前处方集决策中的作用,将CER与建模进行比较,讨论CER未来可能的使用方式,并描述CER的资金来源。

总结

虽然来自不同类型机构(如药品福利管理(PBM)公司和MCO)的决策者对CER可能有不同的定义和期望,但包括处方集决策者在内的利益相关者圆桌会议的大多数思想领袖都认为,CER有能力加强处方集决策,具有一定价值。处方集决策者或许能够利用CER,在福利设计、合同签订、有条件报销、绩效薪酬及其他替代定价安排等领域,更好地为其覆盖决策提供依据。真实世界的CER需要改进健康信息技术基础设施,以更好地获取与价值相关的信息。联邦政府被视为CER背后的关键推动者和资金来源,特别是在基础设施和方法开发方面,而制药行业将调整临床开发并创造越来越多的CER证据。然后需要将CER应用于确定价值(或成本效益)。

结论

预计CER将继续作为处方集决策的一个有价值的组成部分不断发展。未来将CER纳入处方集决策需要联邦政府和学术界的引领、健康信息技术基础设施的改进、持续的资金投入,以及改进和更一致的方法。

相似文献

1
Implementing CER: what will it take?
J Manag Care Pharm. 2012 Jun;18(5 Supp A):S19-29. doi: 10.18553/jmcp.2012.18.s5-a.S19.
2
Can CER be an effective tool for change in the development and assessment of new drugs and technologies?
J Manag Care Pharm. 2012 Jun;18(5 Supp A):S06-11. doi: 10.18553/jmcp.2012.18.s5-a.S06.
3
Looking at CER from the managed care organization perspective.
J Manag Care Pharm. 2012 May;18(4 Suppl A):S13-6. doi: 10.18553/jmcp.2012.18.S8-A.S13.
4
Bringing liraglutide to market: a CER case study.
J Manag Care Pharm. 2012 Jun;18(5 Supp A):S12-8. doi: 10.18553/jmcp.2012.18.s5-a.S12.
5
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
Value Health. 2009 Nov-Dec;12(8):1086-99. doi: 10.1111/j.1524-4733.2009.00605.x. Epub 2009 Sep 10.
6
7
Looking at CER from the pharmaceutical industry perspective.
J Manag Care Pharm. 2012 May;18(4 Suppl A):S9-12. doi: 10.18553/jmcp.2012.18.s4-a.S09.
8
Looking at CER from Medicare's perspective.
J Manag Care Pharm. 2012 May;18(4 Suppl A):S5-8. doi: 10.18553/jmcp.2012.18.S8-A.S5.
9
Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges.
J Manag Care Spec Pharm. 2016 Jun;22(6):609-16. doi: 10.18553/jmcp.2016.22.6.609.
10
AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.
J Manag Care Spec Pharm. 2016 Jul;22(7):826-31. doi: 10.18553/jmcp.2016.22.7.826.

引用本文的文献

1
Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges.
J Manag Care Spec Pharm. 2016 Jun;22(6):609-16. doi: 10.18553/jmcp.2016.22.6.609.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验